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Intervention for valvular heart disease poses unique clinical challenges in cardiology because
the diseases are of relatively low prevalence, the interventions do not lend themselves to
randomized comparative trials, and important clinical end points are assessed only after
decades of follow-up. In addition, continuing advances in prosthetic heart valve technology
make follow-up a moving target because long-term data by definition are available only for
older prostheses. Newer tissue and mechanical prostheses afford superior hemodynamics
compared with their older counterparts, and data suggest that durability and patient mortality
are superior with newer compared with older bioprostheses. Arbitrary cutoffs dictating valve
choice based predominantly on patient age may not give appropriate weight to individual
patient perspectives. In educating and counseling patients regarding choices in heart valve
prostheses, the clinician should help the patient weigh the relative merits for the individual
patient of projected mortality, valve durability, and requirement for anticoagulation, with
associated freedom from re-operation, hemorrhagic and thromboembolic risk, and impact on
lifestyle. (J Am Coll Cardiol 2003;42:1717–9) © 2003 by the American College of
Cardiology Foundation
Valvular heart disease and heart valve surgery pose unique
clinical challenges compared with other cardiovascular dis-
eases. As examples, the treatment of congestive heart failure
and acute coronary syndromes have been revolutionized in
the past few years by large, multi-center, randomized,
placebo-controlled trials with statistically (and clinically)
significant end points available in months if not in a few
years. Valvular heart disease and heart valve surgery, how-
ever, do not lend themselves to similar investigations.
Valvular heart disease is far less prevalent and its clinical end
points far more indolent; clinical outcomes associated with
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prosthetic heart valves (PHVs) are of interest decades later,
rather than acutely after intervention; and heart valve
surgery does not lend itself to randomization. Other than
two trials conducted nearly 30 years ago, there are no (and
are unlikely to be any) large-scale randomized comparisons
between valve prostheses. In addition, advances in valve
technology make the determination of valve durability a
moving target: by nature, 15-year durability data exist for
valves that now may be obsolete. For these reasons, clini-
cians are forced to draw conclusions and make recommen-
dations based on incomplete information, extrapolating
from limited data, clinical experience, and common sense.
In short, for PHV choices, randomized data alone are
insufficient to dictate clinical practice.
The recent review in the Journal (1) concerning choices in
PHVs raises important issues with respect to how physicians
should inform patients and recommend therapy when ex-
isting data are incomplete or imperfect. The review draws
heavily on the randomized trials performed in the late 1970s
(2,3). Based on the assessment that outcomes are the same
for newer prostheses, the review perpetuates traditional
recommendations that tissue valves are appropriate for old
patients and mechanical valves are appropriate for all others.
But much in medicine has changed in the ensuing decades
since these data were derived, raising questions of how to
extrapolate data from these trials to modern practice.
New valves versus old valves. The Edinburgh heart valve
trial (2) was conducted between 1975 and 1979; the Veter-
ans Affairs trial (3) was conducted between 1977 and 1982.
In these trials, late structural deterioration occurred more
often with bioprostheses, which was felt to limit their
usefulness among patients 65 years of age. Because there
are no randomized trials comparing valve prostheses that
enrolled patients after 1982, the clinician must draw con-
clusions about old versus new prostheses based on extrapo-
lation of data.
In the decades since these trials were performed, the
evolution of tissue technology has resulted in newer bio-
prostheses with superior durability. For example, the first-
generation Hancock MO bioprosthesis (Medtronic, Inc.,
Minneapolis, Minnesota) was fixed at high pressure using
no tissue treatment to mitigate calcification, whereas the
second-generation Hancock II bioprosthesis used low-
pressure fixation and an early form of tissue anticalicification
treatment. The 15-year actuarial freedom from structural
valve deterioration was 57  4% for the first-generation
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valve in a population 69 years of age at the time of
implantation (4) and 81  5% for the second-generation
valve in a population 65 years of age at the time of
implantation (5). Although long-term data are lacking for
yet newer devices, data from animal studies (6) and early
human experience (7–9) suggest that third-generation bio-
prostheses will be even more durable compared with earlier
devices. Significantly, case-controlled studies of newer ver-
sus older bioprostheses demonstrate statistically significant
survival advantages associated with some newer bioprosthe-
ses (10–13).
In addition to advances resulting in greater bioprosthesis
durability and lower patient mortality, both tissue and
mechanical prostheses have evolved to provide superior
hemodynamics compared with older counterparts. For bio-
prostheses, this includes supra-annular seating and changes
in sewing ring shape and strut materials that provide greater
orifice area, as well as the development and ongoing
refinement of stentless aortic bioprostheses (7,8). Similarly,
mechanical prostheses have evolved to provide larger effec-
tive orifice area and superior hemodynamics compared with
earlier valves (14). Although it remains debatable as to
whether hemodynamics impact patient mortality (15,16),
there is no question that superior prosthesis hemodynamics
minimizes the occurrence of symptomatic prosthesis-patient
mismatch. Albeit in the absence of randomized, double-
blind trials, there are ample data to suggest that in hemo-
dynamics, bioprosthesis durability, and mortality, good
“new” valves are superior to good “old” valves.
Mechanical versus tissue. In the randomized trials be-
tween mechanical and tissue valves that were performed in
the late 1970s, there was either a trend (2) or statistical
significance (3) favoring improved survival in association
with a mechanical prosthesis. Freedom from re-operation
was superior with a mechanical prosthesis, with higher rates
of bioprosthesis failure among patients 65 years of age.
However, freedom from all valve-related complications for
tissue and mechanical prostheses was indistinguishable at 12
years (Fig. 1) (3). (Morbidity among patients with a
bioprosthesis was composed predominantly of late structural
failure, whereas morbidity among patients with a mechan-
ical prosthesis occurred largely as the result of a constant,
cumulative occurrence of major hemorrhage.) Although
physicians concentrate on mortality and freedom from
re-operation as dominant end points, patients may be more
interested in avoiding all valve-related morbidity after sur-
gery. Using this end point, bioprostheses were superior to
mechanical valves prior to 12 years after surgery and were
equivalent thereafter.
In the decades since these trials were performed, antico-
agulation therapy has become more refined, with closer
control of anticoagulation raising the possibility that bleed-
ing rates in a similar trial would now be lower. Concur-
rently, as previously described, freedom from structural valve
deterioration is superior for newer compared with older
bioprostheses owing to advances in tissue technology that
result in mitigation of calcification. Since the randomized
trials were performed, there have been changes that favor-
ably affect morbidity and mortality for both tissue and
mechanical prostheses. Extrapolating from available data to
modern practice, it is likely that freedom from valve-related
complications continues to favor bioprostheses early after
surgery, that total complications are similar for mechanical
and tissue valves late after surgery, and that the curves would
likely now superimpose later than 12 years after surgery.
Differences between tissue prostheses. There are no large
prospectively randomized comparisons among tissue pros-
theses, and published comparisons often involved dissimilar
populations. In such circumstances, the devil is in the
details. The conclusion that pericardial valves have superior
durability to porcine tissue valves (1,17) may be flawed when
the pericardial valve was studied in a population substan-
tially older than that for the porcine valve and the porcine
valve used in the comparison was a first-generation valve no
longer in clinical use. As already described, second-
generation porcine valves have greater 15-year freedom
from structural deterioration compared with first-generation
prostheses, and there is reason to believe that there is
Figure 1. Freedom from all valve-related complications for tissue and
mechanical prostheses (from Veterans Affairs trial [3], reprinted with
permission from the American College of Cardiology Foundation). Mor-
bidity was composed predominantly of late structural failure among
patients with a bioprosthesis and cumulative occurrence of major hemor-
rhage among patients with a mechanical prosthesis. Freedom from all
valve-related complications for tissue and mechanical prostheses was
indistinguishable at 12 years AVR  aortic valve replacement; MVR 
mitral valve replacement.
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incremental improvement associated with third-generation
bioprostheses. In short, there are no available data to suggest
that modern pericardial bioprostheses have any advantage
over modern porcine bioprostheses. To the contrary, data
reported in similar populations suggest equivalent actuarial
and actual freedom from structural valve deterioration at 15
years for pericardial and porcine bioprostheses (Table 1)
(5,18).
Patient quality of life. There are ample data to show that,
regardless of prosthesis choice, mortality is higher among
patients after valve replacement than among age-matched
controls. Further, any differences in mortality found among
prostheses are of small magnitude and of arguable clinical
relevance. As such, in addition to end points of mortality
and valve-related morbidity, prosthesis choices should take
into consideration the difficult-to-quantify end point of
patient quality of life after valve replacement. Individual
patients may place different emphasis on mortality, freedom
from re-operation, risk of thromboembolism (stroke), risk
of anticoagulation-related hemorrhage, and the lifestyle
modification required with chronic anticoagulation. When
given the chance, some patients choose to accept a near
certainty of requiring re-operation 10 to 20 years in the
future in exchange for the benefit of avoiding anticoagula-
tion, whereas others opt to minimize the likelihood of
re-operation.
As physicians who counsel and help educate our patients
before valve surgery and who continue to care for them after,
we should allow greater latitude in the options that we
present. Simple algorithms that assign patients under an
arbitrary age to receive a mechanical prosthesis minimize
our role to help optimize patient quality of life. If there is a
new “state-of-the-art” for internists and cardiologists in
valve surgery and prosthesis choices, it lies in understanding
the developments in the field and how these changes can
favorably impact our patients’ lives.
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Table 1. 15-Year Freedom From SVD of Porcine and Pericardial Aortic Valve Bioprostheses








David et al. (5) Hancock II (porcine) 1982–1994 670 65  12 81  5% 90  3%
Banbury et al. (18) Carpentier-Edwards (pericardial) 1981–1984 267 65  12 77%* 90%*
*Standard deviation not reported.
SVD  structural valve deterioration.
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